On Monday, the world of science awoke to news that suddenly cast uncomfortable doubt on many of the past five years’ major breakthroughs: A new paper had identified a possible barrier to using the revolutionary gene-editing tool CRISPR-Cas9 in humans. The news incited a temporary hysteria that sent the stocks of all…
Source: Gizmodo – Biotech Stocks Drop After Troubling CRISPR Study, but Gene Editing Is Still the Future